Last reviewed · How we verify
N-methyl-pyrrolidone
At a glance
| Generic name | N-methyl-pyrrolidone |
|---|---|
| Also known as | NMP |
| Sponsor | Peter MacCallum Cancer Centre, Australia |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Assessing Safety of Cervical Spine Fusion With NMP®
- Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion
- NMP in Relapsed / Refractory Myeloma (PHASE1)
- Effect of Three Periodontal Therapies in Current Smokers and Non-Smokers (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- N-methyl-pyrrolidone CI brief — competitive landscape report
- N-methyl-pyrrolidone updates RSS · CI watch RSS
- Peter MacCallum Cancer Centre, Australia portfolio CI